Noxiptiline

Noxiptiline

SCHEMBL49824

CN(C)CCON=C1c2ccccc2CCc2ccccc21

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 6/20 0.52
HTR3E A5X5Y0 5/20 0.52
HTR3B O95264 5/20 0.52
HTR3D Q70Z44 5/20 0.52
HTR3C Q8WXA8 5/20 0.52
HRH1 P35367 5/20 0.49
DRD2 P14416 4/20 0.49
HTR2A P28223 4/20 0.49
SLC6A2 P23975 3/20 0.49
SLC6A4 P31645 3/20 0.49
HTR1A P08908 3/20 0.49
HTR2C P28335 3/20 0.49
HTR2B P41595 3/20 0.49
SLC22A1 O15245 2/20 0.49
CACNA1F O60840 2/20 0.49
CHRM2 P08172 2/20 0.49
CHRM4 P08173 2/20 0.49
CHRM5 P08912 2/20 0.49
ADORA3 P0DMS8 2/20 0.49
CYP2D6 P10635 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Noxiptiline SCHEMBL29358436 1.00 HTR3A (0.52) HTR3AHTR3EHTR3BHTR3DHTR3C
Noxiptiline SCHEMBL1649695 0.98 HTR3A (0.51) HTR3AHTR3EHTR3BHTR3DHTR3C
Noxiptiline SCHEMBL28221925 0.83 SLC6A2 (0.63) HTR3AHTR3EHTR3BHTR3DHTR3C
SCHEMBL11670230 0.79 HTR3E (0.50) HTR3AHTR3EHTR3BHTR3DHTR3C
SCHEMBL9082805 0.79 CES1 (0.38) HTR3AHTR3EHTR3BHTR3DHTR3C
Hydrochloric Acid SCHEMBL11669953 0.78 HTR3E (0.49) HTR3AHTR3EHTR3BHTR3DHTR3C
SCHEMBL11755077 0.76 HRH1 (0.53) HTR3AHTR3EHTR3BHTR3DHTR3C
SCHEMBL11759087 0.73 HRH1 (0.50) HTR3AHTR3EHTR3BHTR3DHTR3C
SCHEMBL16474094 0.72 PPARG (0.44) ALDH1A1LMNAMAPTKDM4E
SCHEMBL12143213 0.71 LMNA (0.51) ALDH1A1LMNAMAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240307386-A1 NOVEL METHODS INTRA-CELLULAR THERAPIES, INC. 2024-09-19 US claimed
EP-4119536-B1 PREPARATION OF A PHARMACEUTICAL INTERMEDIATE DIPHARMA FRANCIS SRL (IT) 2024-08-14 EP claimed
US-20230381168-A1 ADJUNCTIVE THERAPY FOR DEPRESSION ANEUROTECH BV (BE) 2023-11-30 US claimed
US-20230053759-A1 PREPARATION OF A PHARMACEUTICAL INTERMEDIATE DIPHARMA FRANCIS S.R.L. (IT) 2023-02-23 US claimed
EP-3801527-A1 NOVEL METHODS Intra-Cellular Therapies, Inc. (US) 2021-04-14 EP claimed
US-20210060009-A1 NOVEL METHODS INTRA-CELLULAR THERAPIES, INC. 2021-03-04 US claimed
EP-3765021-A1 NOVEL METHODS Intra-Cellular Therapies, Inc. (US) 2021-01-20 EP claimed
US-20200390698-A1 URETHRAL DEVICES FOR TREATMENT OF PATHOLOGICAL UROLOGICAL CONDITIONS INURA MEDICAL AG (CH) 2020-12-17 US claimed
US-20200038420-A1 AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION ENTERIN, INC. (US) 2020-02-06 US claimed
WO-2019178484-A1 NOVEL METHODS INTRA-CELLULAR THERAPIES, INC. (US) 2019-09-19 WO claimed
EP-1424068-A1 Process for the preparation of pellets comprising a tricyclic or tetracyclic antidepressant and pharmaceutical compositions comprising these pellets Oramon Arzneimittel GmbH (DE) 2004-06-02 EP claimed
EP-1417165-A2 DRUGS FOR CHRONIC PAINS Nicox S.A. (FR) 2004-05-12 EP claimed
US-20040076648-A1 Topical compositions and methods for treating pain EPICEPT CORPORATION 2004-04-22 US claimed
US-20030082214-A1 Topical compositions and methods for treating pain DISCOVER GROWTH FUND, LLC (VI) 2003-05-01 US claimed
WO-2003015699-A2 TOPICAL COMPOSITIONS AND METHODS FOR TREATING PAIN EPICEPT CORPORATION (US) 2003-02-27 WO claimed
WO-2003000642-A2 DRUGS FOR CHRONIC PAINS NICOX S.A. (FR) 2003-01-03 WO claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0775128-A1 PREPARATION OF IMMUNOGENS AND OTHER CONJUGATES OF DRUGS Dade Chemistry Systems Inc. (US) 1997-05-28 EP claimed
WO-1996040664-A2 PREPARATION OF IMMUNOGENS AND OTHER CONJUGATES OF DRUGS DADE CHEMISTRY SYSTEMS INC. (US) 1996-12-19 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210060009-A1 NOVEL METHODS HTR2A, HTR3B, HTR1A HTR3A 8/4885HTR3E 14/4885HTR3B 2/4885
US-20200038420-A1 AMINOSTEROL COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING DEPRESSION HSD17B7, CYP17A1, HSD17B2 HTR3A 94/4885HTR3E 407/4885HTR3B 143/4885
US-20240307386-A1 NOVEL METHODS OPRL1, HTR2A, OPRM1 HTR3A 13/4885HTR3E 37/4885HTR3B 8/4885
US-20230053759-A1 PREPARATION OF A PHARMACEUTICAL INTERMEDIATE PMP22, PYGB, COQ8A HTR3A 1018/4885HTR3E 1192/4885HTR3B 719/4885
US-20230381168-A1 ADJUNCTIVE THERAPY FOR DEPRESSION HTR2A, HTR3B, HTR5A HTR3A 8/4885HTR3E 15/4885HTR3B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.